- Home
- About Us
- Service
- Application
- Technology
- Resource
- Contact Us
News and Events
Global Links | HaploX Hong Kong Lab Open Day Successfully Concludes!
2026-06-03
On May 28, 2026, partners from Europe, Southeast Asia, and Hong Kong gathered at the HaploX Hong Kong Science Park Laboratory for an immersive Open Day.
During guided lab tours, attendees experienced HaploX's end-to-end precision medicine capabilities firsthand through close observation and interaction, gaining a deep understanding of its full-chain workflows from sample processing to data interpretation, as well as an intuitive appreciation of its quality control systems and multi-omics platforms.
Jason Zhao, Vice President of HaploX Group and CEO of HaploX Global, welcomed the guests, shared HaploX's mission, "Innovating through technology to enhance quality of life," and conveyed the company's readiness to partner and collaborate.
The Product Marketing Manager Fengxiang Bi and Business Development Manager Yingxiang Li showcased HaploX's comprehensive precision oncology solutions, including companion diagnostics for targeted therapy selection, early cancer screening through non-invasive liquid biopsy, recurrence monitoring via MRD surveillance, and translational research support enabled by multi-omics platforms.
Key technological highlights featured:
- AI-powered multi-omics analysis that delivers end-to-end analytics from raw data to biological interpretation, extracting multi-layer insights from limited samples to significantly accelerate clinical translation.
- TCR deep learning for immune profiling, which analyzes T-cell receptor diversity and antigen specificity to support immunotherapy efficacy prediction and personalized vaccine development.
- GeneBrain(TM) NGS Intelligent Analysis System, which enables full automation from raw sequencing data to clinical reports, dramatically reducing operational complexity for hospital pathology departments and regional testing centers.
Clinical experts from Hong Kong and Southeast Asia discussed AI and multi-omics applications in oncology, addressing clinical translation, data quality, and implementation challenges. Representatives from all parties also shared their platform strengths and collaborative pathways with HaploX for global synergy.
During the event, HaploX signed agreements with multiple partners to deepen future collaboration across joint product development, market promotion, and co-built service networks.
HaploX will keep innovating in AI-driven liquid biopsy, intelligent interpretation, and integrated multi-omics to advance global oncology care with partners worldwide.
